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Abstract
Background: The plasma protein α2-antiplasmin (α2AP) is cross-linked to fibrin in blood clots by
the transglutaminase factor XIIIa, and in that location retards clot lysis. Competition for this effect
could be clinically useful in patients with thrombosis. We hypothesized that fusion of N-terminal
portions of α2-antiplasmin to human serum albumin (HSA) and production of the chimeric proteins
in Pichia pastoris yeast would produce a stable and effective competitor protein.
Results: Fusion protein α2AP(13-42)-HSA was efficiently secreted from transformed yeast and
purified preparations contained within a mixed population the full-length intact form, while fusions
with longer α2AP moieties were inefficiently secreted and/or degraded. The α2AP(13-42)-HSA
protein, but not recombinant HSA, was cross-linked to both chemical lysine donors and fibrin or
fibrinogen by factor XIIIa, although with less rapid kinetics than native α2AP. Excess α2AP(13-42)-
HSA competed with α2AP for cross-linking to chemical lysine donors more effectively than a
synthetic α2AP(13-42) peptide, and reduced the α2AP-dependent resistance to fibrinolysis of
plasma clots equally effectively as the peptide. Native α2AP was found in in vivo clots in rabbits to
a greater extent than α2AP(13-42), however.
Conclusion: In this first report of transfer of transglutamination substrate status from one plasma
protein to another, fusion protein α2AP(13-42)-HSA was shown to satisfy initial requirements for
a long-lasting, well-tolerated competitive inhibitor of α2-antiplasmin predicted to act in a clot-
localized manner.
Background
Proteins contain domains, substructures with conserved
sequence or structural similarity [1]. The majority of
eukaryotic proteins contain multiple domains, ones that
have apparently arisen via "domain accretion" resulting
from duplication and recombination of the domain-
encoding genes [2]. Biotechnological approaches mimic
this principle, through the engineering of gene fusions to
create expressed proteins, ones combining formerly sepa-
rate components into a single polypeptide chain. Com-
monly, the rationale is to slow the clearance from the
circulation of injectable protein-based therapeutic agents,
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or to otherwise stabilize such peptides or proteins. Either
immunoglobulins or albumin have been widely used for
this purpose [3].
Mammalian albumins are abundant proteins found in
blood plasma at mean concentrations of 0.6 – 1.0 mM [4],
of 584–585 amino acids in length [5,6]. Unlike most
plasma proteins, albumin is not glycosylated, but it never-
theless exhibits a long circulatory half-life [4,7] of 19 days
in humans [4]. Recycling of albumin through the major
histocompatibility complex-related Fc receptor for IgG
(FcRn) has been shown to contribute to its circulatory lon-
gevity [8,9]. Productive fusion to albumin has been dem-
onstrated for such diverse proteins as interleukin-2 [10],
atrial natriuretic peptide [11], interferon [12], butrylcho-
linesterase [13] and coagulation factor VII [14]. In the
context of improving therapies for thrombosis, our labo-
ratory has explored albumin fusion to improve the phar-
macokinetics of small proteins like the thrombin
inhibitor hirudin [6,15], the platelet aggregation antago-
nist barbourin [16,17], and related peptides[18].
Recently, we conceived a new strategy to use albumin
fusion to counter thrombosis, by transferring a property
of another plasma protein, α2-antiplasmin (α2AP), to
albumin.
α2AP is a plasma glycoprotein of the serine proteinase
(serpin) superfamily that regulates fibrinolysis, the natu-
ral process of blood clot lysis [19]. It binds plasmin using
a C-terminal lysine-rich domain and inhibits it by form-
ing a stable, covalent serpin-enzyme complex [20]. It is
also cross-linked into fibrin clots, and in that location
slows clot lysis by inhibition of plasmin [21]. Chemical
[22] or mutational [23] inactivation of the α2AP reactive
centre loop (RCL) yields a protein that competes with
native α2AP for cross-linking to fibrin, but which cannot
inactivate plasmin. Consequently, clot lysis is accelerated.
Activated factor XIII (fXIIIa) mediates the cross-linking of
lysines on fibrin and glutamines on α2AP [24]. The prin-
cipal cross-linked residue on α2AP is Q14, although other
residues can also be modified, and synthetic peptides con-
taining this site are weaker substrates for transglutamina-
tion than intact or RCL-inactivated α2AP [25].
As a glycoprotein and conformationally sensitive serpin
[26], α2AP can be difficult to express efficiently in recom-
binant form. Recombinant human serum albumin (HSA),
in contrast, is efficiently expressed at exceptionally high
yield in Pichia pastoris yeast systems [27]. We hypothesized
that N-terminal portions of α2AP, when fused to HSA,
would confer upon it the ability to be cross-linked to
fibrin, and to interfere with α2AP-mediated delays in clot
lysis. Furthermore, we thought that display on albumin
could present Q14 in a more favourable conformation for
cross-linking than when it is present in a short peptide.
Reasoning that the cross-linking site(s) might require
additional motifs from α2AP, we compared the produc-
tion and properties of three overlapping, C-terminally
truncated portions of α2AP fused to HSA.
Methods
DNA Manipulations
Four plasmids were constructed to enable expression of
HSA and three α2AP-HSA fusion proteins as C-terminally
hexahistidine-tagged Pichia pastoris expression products.
All oligonucleotides were synthesized and all constructs
subjected to confirmatory DNA sequencing at MOBIX
Lab, a McMaster University core facility. PCR employed
Phusion™ high fidelity heat-stable DNA polymerase
(NEB). Standard molecular biological protocols for puri-
fication of DNA from agarose gels, DNA restriction and
ligation, transformation of E. coli Top10 (Invitrogen) to
ampicillin resistance, and plasmid mini-DNA prepara-
tions were employed. First, the HSA DNA was manipu-
lated for expression by PCR amplification, using
oligonucleotides ML12007 (5'-CATGGAATTC TTAAT-
GGTGA CGGTGATGGT GTAAGCCTAA GGCAGCTCGA
CTTGCAGCAA C-3'), ML12008 (5'-GATCCTCGAG
AAAAGAGACG CACACAAGAG TGAGGTTGC-3'), and
plasmid pC3HFUS [28] as a template. The resulting 1788
bp amplification product was restricted with XhoI and
EcoRI and the inserted between these sites in
pPICZ9ssamp [15] to form pPICZ9ssHSAH6. PCR prod-
ucts A, B, and C were then generated using as a template
the human α2AP-encoding plasmid pBAD-H6α2AP [29].
Codons 13–42 were mobilized using oligonucleotides ML
17226 (5'-ACGTCTCGAGA AAAAGAAACC AGGAG-
CAGGT GTCCCC-3') and ML 17225 (5'-ACGTGGTAC
CGACTCCTGG GGGACTCTTC AG-3') to form product A.
Codons 13–73 were obtained using ML 17226 and ML
17227 (5'-AGCTGGTACCC CTGGTGAGCC ACCAG-
GGAGA AC-3') in product B. Codons 13–109 were ampli-
fied using ML 17226 and ML 17228 (5'-AGCTGGTACC
CCCAGCACCT TTGCAGCCTC TG-3') to yield product C.
The HSA cDNA was then PCR-amplified with oligonucle-
otides ML 12006 (5'-CATGCGGTAC CACAAGAGTG
AGGTTGCTC-3') and ML 12007 (5'-GTTGCTGCAA
GTCAGGCTGC CTTAGGCTTA CACCATCACC ATCAC-
CATTA AGAATTCCAT G-3') to produce fragment D. A, B,
and C were restricted with XhoI and KpnI and D with
KpnI and EcoRI. D was then separately combined with A,
B, and C, and inserted between the XhoI and EcoRI sites
of pPICZ9ssamp [15], forming plasmids pPICZ9ss-
α2AP(13-42)-HSAH6, pPICZ9ss-α2AP(13-73)-HSAH6,
and pPICZ9ss-α2AP(13-109)-HSAH6. Each completed,
sequence-validated plasmid listed above was used to
transform Pichia pastoris strain X33 to Zeocin (Invitrogen)
resistance as described [18].BMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
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Fusion protein expression, purification, and 
characterization
HSA fusion proteins were purified from media condi-
tioned by transformed Pichia pastoris cells and induced
with 0.5% vol/vol methanol, as previously described for
rabbit serum albumin (RSA) fusion proteins [18,30].
Briefly, media was neutralized, separated from cells by
centrifugation, treated with protease inhibitors (5 mM
benzamidine and 0.1 mM phenylmethylsulfonyl fluo-
ride), and purified using Ni-NTA agarose (Qiagen). Puri-
fied proteins were analyzed by SDS-PAGE and
immunoblotting using polyclonal goat anti-human α2AP
antibodies (Affinity Biologicals) and murine monoclonal
anti-HSA antibodies (Genway Biotech). They were also
characterized by automated Edman degradation at the
Advanced Protein Technology Centre of the Hospital for
Sick Children, Toronto, Canada. The same facility was the
source for synthetic peptides corresponding to α2AP(13-
42) and to a plasma protein unrelated to this study,
heparin cofactor II residues 54–75. The former peptide
was shown to contain a single main peak, corresponding
to the predicted molecular mass of 3100 Da, by time-of-
flight mass spectrometry performed by the manufacturing
facility.
Transglutamination assays using chemical lysine donors
FXIIIa-catalyzed transglutamination of plasma-derived
α2AP and recombinant α2AP-HSA fusion proteins was
tested using both artificial (dansyl cadaverine and bioti-
nylated pentylamine) and natural (fibrinogen) lysine
donors, in protocols modified from the literature [31].
Purified fXIII, thrombin, and α2AP were purchased from
Enzyme Research Labs. Human proteins were used in all
cases in reactions at 37°C. Using dansyl cadaverine
(Sigma) at 0.5 mM, substrate proteins (7.14 μM) were
combined with FXIII (1.52 μM) in Tris-buffered saline (20
mM Tris-Cl pH 7.5, 150 mM NaCl) containing 10 mM
CaCl2 and 0.5 mM dithiothreitol (DTT). Reactions were
initiated by the addition of thrombin to 5.0 IU/ml and
terminated at specific intervals by addition of disodium
EDTA to 10 mM. Transglutamination resulted in protein
substrates becoming visible under ultraviolet illumina-
tion after SDS-PAGE. Biotinylated pentylamine (BPA; EZ-
Link pentylamine-biotin, Pierce) was used under similar
conditions with the following exceptions: BPA was substi-
tuted for dansyl cadaverine, at 10 mM, FXIII was 0.76 μM,
CaCl2 was 5 mM and thrombin was 1.0 U/ml. Trans-
glutamination in this case resulted in transfer of a biotin
group to substrates. Reactions were visualized on 8% SDS-
polyacrylamide gels following transfer to nitrocellulose
and blocking with 4.0 mg/ml BSA in TBS/0.2% Tween 20
(TBST), using streptavidin conjugated to horseradish per-
oxidase (Cedarlane Laboratories) at a 1:5000 dilution.
Chemiluminescent substrate cleavage was captured on
Biomax XAR scientific imaging film (Kodak). In some
experiments band intensity was quantified using UN-
Scan-it software (Silk Scientific) and a scanning unit
(Canon).
Transglutamination of fibrin(ogen)
FXIIIa-catalyzed transglutamination of the natural sub-
strate fibrinogen was assessed using SDS-PAGE and
immunoblotting of cross-linking reactions. FXIII (100
nM) was quantitatively activated by incubation with 5.0
IU/ml thrombin for 5 minutes at 37°C prior to thrombin
inactivation by addition of Phe-Pro-Arg chloromethylke-
tone (FPRck; Calbiochem) to 10 μM. This step eliminated
thrombin cleavage of chromogenic substrate S2238
(Diapharma). FXIIIa (at 50 nM final concentration) was
then introduced into crosslinking reactions containing
6.0 μM fibrinogen (Sigma), and 1.0 μM substrate proteins
in TBS containing 10 mM CaCl2. Reactions were stopped
by addition of SDS to 1% w/vol, DTT to 50 mM, and urea
to 4 M, followed by addition of 0.25 volumes of 4 × SDS
loading buffer (125 mM Tris-Cl pH 6.8, 5% SDS, 25%
(vol/vol) glycerol, 400 mM DTT, 0.1 mg/ml bromophe-
nol blue). Reactions were electrophoresed on 8% SDS
polyacrylamide gels under reducing conditions, and
either stained with Coomassie Brilliant Blue or probed
with antibodies on immunoblots as described above.
In vitro clot lysis
Human plasma immunodepleted to < 1% normal α2AP
levels (ERL) was diluted 1:1 in TBS to final concentrations
of 10 mM CaCl2, 5 nM thrombin, and 0.125 nM tissue-
type plasminogen activator (tPA; single-chain, recom-
binant tPA, 60 kDa, carrier-free, purchased from Genen-
tech by Dr. Ed Pryzdial, Canadian Blood Services, and
University of British Columbia Centre for Blood Research,
and kindly donated for our use). Reactions (50 μl) were
carried out in microtiter plate wells, and clot formation
and lysis was monitored by following changes in turbid-
ity, using an ELx808 plate reader (BioTek Instruments) set
to take absorbance readings at 340 nm every 30 seconds
for 4 hours. The area under the curve of the resulting pro-
file was measured using data from such experiments trans-
ferred to GraphPad Prism 4.0 (GraphPad Software).
Wessler-type in vivo clot incorporation
The propensity of injected proteins to remain in an in vivo
clot exposed to flowing blood was determined in anesthe-
tized New Zealand White rabbits using a Wessler-type
model, in a protocol modified from the literature [32-34].
Purified human fibrinogen (Sigma) and recombinant
proteins were iodinated using the Iodogen method as
described by the manufacturer (Pierce), using either
sodium  125I or 131I. Unincorporated radioactivity was
removed by exhaustive dialysis versus phosphate-buffered
saline. Specific activities of labelling exceeded 1 × 109
cpm/mg. Anaesthetized rabbits were cannulated via theBMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
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carotid artery and subjected to a medial incision in the
neck to expose the jugular veins. Three ml of whole blood
was drawn via the cannula, and anticoagulated with 1/9th
volume of 3.8% w/vol sodium citrate. Two centimetre
long sections of the right and left jugular veins were iso-
lated, emptied of blood, and blocked off by bulldog
clamping. Clotting of the anticoagulated, autologous
whole blood was initiated by combining it with warm
(37°) human thromboplastin reagent Thromborel S
(Dade Behring) in a 1:4 (vol:vol) ratio, supplementing it
to 33 × 106cpm/ml 125I-fibrinogen and 131I-recombinant
protein, and the clotting blood (0.15 ml) was re-intro-
duced into the isolated segments. The process was then
repeated for the other jugular vein. After 30 minutes of
stasis, the clamps were removed, and blood flow restored.
One hour later, the jugular veins were opened by longitu-
dinal incision, and the clots were removed, weighed, and
γ-counted in a Auto Gamma 5530 Minaxi γ counter (Per-
kin Elmer), with windows set to discriminate between 125I
and 131I. Values were summed for left and right jugular
veins for each animal.
Statistical analysis
Statistical tests were performed using GraphPad Instat ver-
sion 3.06 (GraphPad Software). Multiple comparisons
used one-way parametric analysis of variation (ANOVA)
with Tukey-Kramer post-tests for assignment of group-
specific differences, while single comparisons employed
Student's t-tests
Results
Expression and characterization of fusion proteins
In human plasma, α2AP is found in two forms: a minor
form of 464 amino acids commencing with Met (Met-
α2AP); and a major form of 452 amino acids that arises
from processing of Met-α2AP at the Pro12-Asn13 bond
(Asn-α2AP). The latter has been reported to be more effi-
ciently cross-linked to fibrin than the former [35]. We
therefore based the 3 α2AP-HSA fusion constructs exam-
ined in this study on the 13–464 Asn-α2AP isoform. As
shown in Fig. 1A, we predicted an increase in polypeptide
chain length of 30, 61, and 97 amino acids for the three
C-terminally hexahisitidinylated fusion proteins versus C-
terminally hexahisitidinylated recombinant HSA made in
the same Pichia pastoris system. This corresponds to
molecular masses of 73,127, 76,575, and 80,379 Daltons,
respectively, as compared to 67,293 for recombinant HSA.
However, as shown in Fig. 1B, comparison of total protein
profiles of conditioned media from cultures programmed
to produce α2AP(13-42)-HSA,  α2AP(13-73)-HSA,
α2AP(13-109)-HSA, and recombinant HSA, showed that
only in the first and last case did expression of an abun-
dant methanol-inducible protein > 65 kDa ensue. Lesser
secretion of the putative α2AP(13-73)-HSA and no
Coomassie-visible expression of α2AP(13-109)-HSA-
related species was apparent. Following concentration
and purification on nickel-chelate affinity columns,
apparently homogeneous preparations of α2AP(13-42)-
HSA and α2AP(13-73)-HSA were obtained (Fig. 1C),
although their apparent co-migration suggested either an
inability to resolve a 7 kDa difference in the electrophore-
sis or truncation. In contrast, a heterogeneous preparation
of  α2AP(13-109)-HSA consisting of multiple bands of
lesser to equal mobility to the other two proteins was
obtained.
Amino acid sequencing of the three preparations shown
in Fig. 1C was attempted. No sequence of α2AP(13-109)-
HSA was obtained. For α2AP(13-73)-HSA, a single
sequence of VAQTGY, corresponding to residues 70-73 of
α2AP and a GY dipeptide introduced by DNA manipula-
tions was obtained. This result indicated near-complete
proteolysis of the intended α2AP(13-73) extension. In
contrast, α2AP(13-42)-HSA was found to contain a mix-
ture of 4 termini depicted in Fig. 1D. These included the
intended full-length sequence, as well as 3 smaller prod-
ucts with N-termini corresponding to L25, Q28, and S38.
Characterization of recombinant fusion proteins as fXIIIa 
substrates
The expression and sequencing results predicted that, of
the α2AP-HSA fusion protein preparations, only α2AP(13-
42)-HSA had the potential to be a substrate for fXIIIa. This
idea was first tested in simple reactions using chemical
lysine donors. As shown in Fig. 2A, in the presence of
biotinylated pentylamine (BPA), plasma-derived α2AP
became biotinylated in a fXIIIa- and calcium ion-depend-
ent manner. Similar transglutamination of the biotin-con-
taining lysyl substrate was observed for α2AP(13-42)-
HSA, with similar kinetics but to a lesser extent. Quantifi-
cation of band intensities revealed the extent of α2AP(13-
42)-HSA transglutamination to be 39, 49, and 59%,
respectively, of that of α2AP at 30, 60, and 90 minutes,
respectively. In contrast, α2AP(13-73)-HSA and α2AP(13-
109)-HSA showed no labelling by BPA, in concordance
with the electrophoretic and sequencing results. The abil-
ity of α2AP(13-42-HSA to be transglutaminated to
another lysine donor, dansyl cadaverine, was also demon-
strated in Fig 2B, although the transfer of dansyl group flu-
orescence to this protein was less than that observed for
α2AP.
In the experiment shown in Fig. 2C, BPA-detected trans-
glutamination of α2AP was carried out in either the pres-
ence of a homogeneous synthetic peptide corresponding
to α2AP (13-42), or the preparation of α2AP(13-42)-HSA
shown to contain mixed N-termini by sequencing. Ten-
and 100-fold molar excesses of the former reduced but did
not eliminate fXIIIa-dependent transglutamination of
α2AP. An unrelated peptide corresponding to heparinBMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
Page 5 of 11
(page number not for citation purposes)
Figure 1 (see legend on next page)BMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
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cofactor II residues 54–75 was without effect at 100-fold
molar excess. In contrast, a 24-fold molar excess of
α2AP(13-42)-HSA abrogated transglutamination of
plasma-derived α2AP, in spite of its heterogeneity at its N-
termini.
Having demonstrated the potential superiority of
α2AP(13-42)-HSA over α2AP(13-42) as a competitor of
α2AP cross-linking of a chemical lysine donor, we next
asked how effectively it was cross-linked to a natural
polypeptide lysine donor, fibrinogen. While fibrin is
thought to be the predominant physiological lysine donor
for α2AP transglutamination, it has been demonstrated
that α2AP can be cross-linked to circulating fibrinogen
[36]. Fibrinogen is a more convenient experimental sub-
strate in that it does not clot, and numerous groups have
used it rather than fibrin to examine cross-linking (e.g.
[37]). We therefore first examined the ability of α2AP(13-
42)-HSA to be cross-linked to fibrinogen, utilising sub-
physiological concentrations of both fibrinogen and
α2AP, in order to compare fairly initial rates. As shown in
Fig. 3A, fXIIIa catalyzed the formation of readily visual-
ized γ-γ chains (migrating between the 85 and 100 kDa
marker positions) and less abundant α polymers (migrat-
ing between the 150 kDa and 200 kDa markers) visible by
Coomassie Blue staining of SDS-gels. α2AP-related pro-
tein cross-linking at the concentrations of these proteins
that were employed required immunoblotting to detect.
As shown in Fig. 3B, higher molecular-weight trans-
glutamination products were detected when plasma-
derived α2AP was combined with fibrinogen and fXIIIa,
whose abundance increased over time and of which a
product migrating near the 170 kDa mass marker was
arguably the most abundant. Similar results were
obtained with α2AP(13-42)-HSA, although it was more
difficult to visualize this fusion protein than α2AP, likely
because of the lesser reactivity of the polyclonal anti-α2AP
with a fusion protein containing only 30 residues of α2AP
(see Fig. 3C, right panel). When aliquots of the same reac-
tions as those shown in Fig. 3C, right panel, were probed
using anti-HSA, an identical pattern was obtained. In con-
trast, no cross-linked products were obtained when
α2AP(13-73)-HSA was substituted for α2AP(13-42)-HSA
in cross-linking reactions (Fig. 3D), even when incuba-
tions were prolonged to 5 minutes. Elimination of either
fibrinogen or fXIIIa from cross-linking reactions abro-
gated complex formation (data not shown); antibody spe-
cificity, for instance the lack of cross-reaction of anti-HSA
monoclonal antibody (Fig. 3D), was as expected. The sim-
ilar size of the cross-linked products reflected the similar
size of glycosylated plasma-derived α2AP and α2AP(13-
42)-HSA; less abundant products of lesser mobility seen
in Figs. 3B and 3C resembled those reported by others in
similar reactions [31,38].
Fusion protein α2AP(13-42)-HSA competes with α2AP in a 
plasma clot
We next sought to determine if α2AP(13-42)-HSA could
compete with a physiologically and clinically relevant
property of α2AP, that of providing resistance to fibrinol-
ysis in clots in which it is cross-linked to fibrin. To ensure
the specificity of the effect, we obtained human plasma
deficient in α2AP. When this anticoagulated plasma was
clotted with thrombin, in the presence of calcium ions
and low concentrations of tPA, clots formed and then
lysed rapidly under the influence of plasmin, whereas if
tPA was left out of the reaction, clots were stable for hours
(compare turbidity profiles 3 and 1 in Fig. 4B). This differ-
ence can be quantified as the area under the turbidity
curve. As shown in Fig. 4A, the addition of increasing
amounts of purified plasma-derived α2AP to this system
progressively delayed clot lysis, as has been reported by
others, for instance by measuring clot lysis times [22].
Having shown the dependence of this effect on α2AP, we
added the protein back to its physiological concentration
of 1.0 μM, noting that fibrinolysis still occurred, as indi-
cated by the downward slope of turbidity profiles 4 and 5
in Fig. 4B, but at greatly attenuated rates. When a 14-fold
molar excess of unrelated peptide HCII 54–75 was added
with the α2AP, there was no change in the resistance to
fibrinolysis. In contrast, use of an identical excess of either
α2AP(13-42) peptide or α2AP(13-42)-HSA fusion protein
α2AP-HSA fusion protein design, expression, and characterization Figure 1 (see previous page)
α2AP-HSA fusion protein design, expression, and characterization. (A) Schematic diagram of proteins. Relevant 
polypeptides are shown in linear form, with important residues identified above each bar. White bars correspond to the N-ter-
minal dodecapeptide sequence removed from Met-α2AP to form Asn-α2AP, shown in grey; HSA is shown in black, and C-ter-
minal hexahistidines are shown as stippled bars. (B) Electrophoretic profile of conditioned media samples taken from P. pastoris 
cultures at the times indicated above the lanes, post-induction with methanol. A Coomassie Blue-stained 10% SDS-polyacryla-
mide gel is shown. Cell lines were transformed with plasmid constructs directing the synthesis of the proteins identified above 
the horizontal lines. Markers on the leftmost lane of the gel are, in kDa: 160; 140; 120; 100; 90; 80; 70; 60; 50; 40; 30; and 25. 
(C) A stained gel similar that in panel B is shown, except that 5 μg of the purified proteins identified above the lanes were elec-
trophoresed. M, markers, same as in panel B. (D) N-termini found in purified α2AP(13-42)-HSA by amino acid sequencing of 
the preparation shown in the leftmost lane of panel C. Numbers above the box identify every fifth amino acid residue in 
α2AP(13-42)-HSA.BMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
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had a dramatic effect in accelerating clot lysis (compare
profiles 6 and 7 to 4 in Fig. 4B). The effect was reproduci-
ble and statistically significant (see Fig. 4C), although the
greater effect of the fusion protein over the peptide did not
reach statistical significance. Similarly, lesser excesses of
peptide or fusion protein reduced the mean area under
the curve in a dose-dependent manner, but one which did
not become significant until 14-fold, the largest amount
of fusion protein we could add without re-concentration
of our stock solution (data not shown).
Factor XIIIa-mediated incorporation of BPA or dansyl cadav- erine into α2AP and fusion proteins Figure 2
Factor XIIIa-mediated incorporation of BPA or dan-
syl cadaverine into α2AP and fusion proteins. (A) Rele-
vant portions of streptavidin blots containing the reaction 
products of the proteins identified below the panels with 10 
mM BPA in the presence of thrombin, FXIII, calcium, and 
7.14 μM test proteins, for the times in minutes shown above 
the lanes, using reaction conditions described in "Methods". 
Lanes labelled "No FXIII" and "No Ca++" correspond to 
reactions identical to those shown for α2AP at 120 minutes, 
with the omission of the listed components. (B) Portions of 
8% SDS-acrylamide gels visualized by ultraviolet transillumi-
nation following fXIIIa-mediated transglutamination of 0.5 
mM dansyl cadaverine to the proteins listed the right of the 
panels. (C) Same as panel A, except that all reactions con-
tained α2AP at 1.7 μM, reacted with BPA, thrombin and FXIII 
in the presence of the concentrations of either α2AP(13-42) 
synthetic peptide (13-42 Pep), α2AP(13-42)-HSA (13-42 FP 
for fusion protein) shown above the lanes. The positions of 
α2AP and α2AP(13-42)-HSA are highlighted at right.
Figure 3BMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
Page 8 of 11
(page number not for citation purposes)
Association of α2AP and recombinant proteins with an in 
vivo clot
While the results of both the transglutamination assays
and the fibrinolysis resistance experiments suggested suc-
cessful transfer to albumin of substrate status associated
with fusion of α2AP(13-42), they also suggested that the
fusion protein was a less effective substrate than α2AP. We
sought to test this conclusion in vivo using a Wessler-type
model. In this protocol, coagulation is initiated in autolo-
gous rabbit blood that is then rapidly introduced into a
clamped-off major blood vessel. Clots are allowed to form
in situ, blood flow is restored, and after aging, the clots are
recovered and analysed. 125I-fibrinogen was co-injected
with a single 131I-labelled protein from a group comprised
of plasma-derived α2AP, recombinant α2AP(13-42)-HSA,
and recombinant HSA. Figure 5 shows the quantification
of the protein-bound radioactivity remaining in the clot at
the end of the procedure, normalized to the amount of
fibrin(ogen) remaining. The most retained protein was
α2AP, followed by α2AP(13-42)-HSA and HSA. While sig-
nificantly more α2AP was found in the clot than HSA, the
amounts of α2AP(13-42)-HSA and HSA that were retained
were not statistically different. The amount of protein
retained in the clot is expected to be the sum of that frac-
tion that is non-covalently trapped and that fraction that
is cross-linked. The results support the concept that
α2AP(13-42)-HSA is a less effective substrate for cross-
linking than α2AP, not only in vitro but also in vivo,
explaining the need for excess fusion protein to compete
the effects of the natural antiplasmin.
Discussion
While it has been known for some time that the principal
site of cross-linking of α2AP resides in the N-terminal sec-
tion of the molecule [31,38], short peptides recreating this
motif are less efficiently incorporated into fibrin than
native α2AP. This difference is shown by the finding that
100- to 1000-fold molar excesses of a synthetic peptide
corresponding to residues 13–24 of α2AP were required to
diminish  α2AP cross-linking to fibrin by 50% [39].
Hypothesizing that anchoring the N-terminal sequence to
a protein would conformationally improve its fitness as a
fXIIIa substrate, we designed three fusion proteins con-
taining overlapping N-terminal portions of α2AP fused to
HSA. These segments were rationally selected on the basis
Figure 4
Cross-linking of α2AP and α2AP(13-42)-HSA by fXIIIa to  fibrinogen Figure 3
Cross-linking of α2AP and α2AP(13-42)-HSA by fXIIIa 
to fibrinogen. FXIII was pre-activated to fXIIIa by thrombin, 
the thrombin inactivated with FPRck, and the fXIIIa then 
combined with fibrinogen and α2AP or α2AP(13-42)-HSA or 
α2AP(13-73)-HSA in transglutamination reactions. Reactions 
were terminated with SDS, DTT, and urea as described in 
"Methods". (A) depicts a Coomassie Blue-stained SDS-poly-
acrylamide gel highlighting the cross-linking of fibrinogen into 
γ-γ dimers (γ-γ) and α-polymers (α). (B) shows an anti-α2AP 
immunoblot of transglutamination reactions containing α2AP 
for the times identified above the lanes; the first lane contains 
α2AP alone. (C), right panel, is identical to B except that 
α2AP(13-42)-HSA was substituted for α2AP; (C), left panel, is 
identical to the right panel except an anti-HSA antibody was 
used. (D) is identical to (C), left panel, except that α2AP(13-
73)-HSA was substituted for α2AP(13-42)-HSA. The position 
of molecular mass markers, is shown to the left or right of 
the panels.BMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
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of the conserved and aligned secondary structural ele-
ments in serpins [40]. Thus, the first selected segment,
α2AP(13-42), terminates at the beginning of helix A, the
second, α2AP(13-73), at the beginning of helix B, and the
third, α2AP (13-109), at the end of combined helices B
and C. In addition, choice of the 13–42 segment deliber-
ately avoided residue C43 and the possibility of interfer-
ing with the correct pairing of the 17 disulphide bonds in
HSA. Finally, Q33 has been reported to be transglutami-
nated to fibrin or fibrin surrogates, albeit at a 10-fold
reduced rate compared to Q14 [31], and it was postulated
that its inclusion might increase the reactivity of the chi-
meric proteins. We had also previously expressed not only
small proteins such as hirudin variant 3 (66 amino acids)
and barbourin (73 amino acids), as well as smaller bar-
bourin- or RGD-containing derivative peptides as N-ter-
minal fusions to rabbit albumin in the Pichia pastoris
system employed in this study, without encountering
either inefficiency or instability of expression [15,16,18].
In spite of this rational design and previous examples of
the soundness of the strategy, the two larger α2AP-HSA
chimerae were inefficiently expressed in Pichia pastoris.
While the extreme nature of this expression problem pre-
vented characterization of α2AP(13-109)-HSA, α2AP(13-
73)-HSA was purified and shown to have been prote-
olyzed at the L69-V70 bond. While we cannot rule out the
possibility that this cleavage occurred during the purifica-
tion process, in spite of the presence of serine protease
inhibitors in all solutions, the diminished yield and
apparent lack of full-length products in conditioned
media samples suggests intracellular proteolysis. In con-
trast, at least some of α2AP(13-42)-HSA protein was pro-
duced in full-length form. In two of the three N-terminally
truncated chimeric proteins also detected in the purified
preparation by N-terminal amino acid sequencing, Q33
was also present and located closer to the N-terminus than
in its natural setting, increasing its potential to contribute
as a substrate. For these reasons we continued to investi-
gate the α2AP(13-42)-HSA, while realising that its func-
tional concentration was probably being underestimated
in our assays.
We found that the α2AP(13-42)-HSA fusion protein was
readily transglutaminated by fXIIIa to both artificial lysine
donors like BPA and dansyl cadaverine, and to the natural
lysine donor fibrinogen. While the rates of these reactions
Localization of radiolabeled proteins in rabbit jugular vein  clots in vivo Figure 5
Localization of radiolabeled proteins in rabbit jugular 
vein clots in vivo. The radioactivity remaining in rabbit jug-
ular vein clots allowed to polymerize in clamped-off vessels in 
situ for 30 minutes in the anesthetized animal, then to age 
with circulation restored for 60 minutes, prior to clot recov-
ery and γ-counting is shown. Clots formed in the presence of 
125I-fibrinogen and 131I-labelled plasma-derived α2AP or 
recombinant α2AP(13-42)-HSA or recombinant HSA. Indi-
vidual data points are the mean of values for both left and 
right jugular veins, shown as the mean of 6 such means ± 
SD). Asterisk indicates the only comparison in the group sig-
nificant (p < 0.05) by paired t-tests.
Effects of α2AP and derivatives on plasma clot formation and  lysis Figure 4
Effects of α2AP and derivatives on plasma clot forma-
tion and lysis. (A) Clot formation and lysis was followed by 
monitoring turbidity (absorbance at 340 nm) every 30 sec-
onds for 4 hours using a plate reader, of clots formed using 
diluted α2AP-deficient plasma containing both 5 nM thrombin 
and 0.125 nM tPA, and taking the area under the turbidity 
versus time curve (AUC). Reactions were supplemented 
with increasing concentrations of purified plasma-derived 
α2AP, and the AUC relative to that of reactions lacking tPA 
reported as a percentage. Results of a single experiment are 
shown. (B) shows turbidity plots for reactions similar to 
those shown in A, under 7 conditions described in the + or - 
table in panel C; for instance, (1) shows stable clot formation 
in the absence of tPA, (3) shows clot formation and rapid 
lysis in the presence of tPA, (4) shows attenuation of clot 
lysis in the presence of 1.0 μM α2AP and (6) and (7) show 
competition of the α2AP effect by 14 μM α2AP(13-42) syn-
thetic peptide (Pep) or α2AP(13-42)-HSA fusion protein (FP), 
respectively. C shows the results of quantification of the 
experiment shown in B and repeated 4 times (n = 3 to 11 ± 
SD), under the conditions summarized below the graph, as 
indicated below the lanes. A control peptide unrelated to 
α2AP corresponding to residues 54–75 of heparin cofactor II 
was used at 14 μM (HCII Pep). Asterisks indicate significant 
differences between groups compared between the horizon-
tal lines (p < 0.05).BMC Biotechnology 2009, 9:15 http://www.biomedcentral.com/1472-6750/9/15
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were noticeably less rapid than that of the fusion protein's
natural counterpart, α2AP, it was clearly a more effective
substrate than its synthetic peptide counterpart, α2AP(13-
42). This finding was shown through the lower concentra-
tions of fusion protein required to compete α2AP cross-
linking under at least some conditions.
The specific mechanism by which presentation of
α2AP(13-42) on the N-terminus of a large protein such as
albumin, rather than in untethered free peptide form,
would increase its reactivity is not clear. Sugimura et al.
also reported productive transfer of peptide sequences as
fXIIIa substrates to the N-terminus of another protein, in
this instance glutathione sulfotransferase [37]. The
requirements for efficient cross-linking of sequences by
fXIIIa to lysine donors are not well understood, although
the suggestion that the reactive glutamine should ideally
be positioned in a highly flexible portion of the substrate
protein is consistent with our findings [39,41]. It is also
likely that the peptide substrates fluctuate between many
different conformations in solution, only some of which
are optimal for interaction with the transglutaminase,
whereas the tethered sequences in the fusion protein con-
text could be constrained in a more optimal conforma-
tion.
Although previous reports have highlighted the possibil-
ity of using chemically or mutationally modified α2AP as
antithrombotic agents, by virtue of their ability to reduce
α2AP-mediated fibrinolytic resistance [22,23], albumin
fusion proteins such as α2AP(13-42)-HSA, with similar
properties, could have significant advantages. α2AP has
been reported to be inefficiently secreted from Pichia pas-
toris yeast [23], would likely have to be prepared in more
expensive mammalian cell culture systems, and has not
been investigated clinically or preclinically as a recom-
binant product in vivo. In contrast, HSA is particularly
efficiently expressed in Pichia pastoris yeast, a scalable sys-
tem ideal for economical large-scale pharmaceutical pro-
duction, and Pichia-derived HSA has been shown to have
equivalent effects to plasma-derived HSA in patients [42].
Recombinant HSA and HSA fusion proteins exhibit the
same or similar plasma longevity to plasma-derived HSA
[12,27]. Moreover, there may be immunogenicity advan-
tages to albumin fusion proteins, particularly ones with
minimized fusion domains. In a comparison of a 17
amino acid peptide-RSA fusion protein containing the
same KGD active antiplatelet sequence found in the 73
amino acid barbourin-RSA fusion protein, the former, but
not the latter, elicited antibody formation [18].
In spite of its biotechnological advantages, α2AP(13-42)-
HSA appears less active in reducing α2AP-mediated fibri-
nolytic resistance in clots than modified α2AP proteins, in
that an approximately 10-fold molar excess of fusion pro-
tein, as opposed to equimolar amounts of modified α2AP,
are required to halve fibrinolytic resistance in plasma clots
in vitro [22,23]. Moreover, α2AP(13-42)-HSA demon-
strated less ability to become clot-associated in an animal
model of thrombosis employed in this study, than native
α2AP. In this regard, α2AP(13-42)-HSA can be viewed as a
prototype fusion protein, one that could likely readily be
improved in several ways: by mutating residues prone to
proteolysis, such as K24 and K37; or by substituting the
α2AP-derived N-terminal extension with more readily
transglutaminated peptides such as those identified by
phage display [37]. Such an optimized modified HSA
could prove therapeutically useful as an antithrombotic
agent, or as an adjunctive drug used in association with
thrombolytic therapy.
Conclusion
An α2AP(13-42)-HSA fusion protein was secreted more
efficiently by transformed Pichia pastoris yeast than chime-
rae containing longer stretches of α2AP. Fusion of the
α2AP motif changed HSA into a substrate for transglutam-
ination by fXIIIa. The order of reactivity with chemical
and physiological lysine donors was α2AP > α2AP(13-42)-
HSA > α2AP(13-42) synthetic peptide. The fusion protein
reduced  α2AP-mediated fibrinolytic resistance when
present at 14-fold molar excess in plasma clots, but was
unable to localize to clots as effectively as α2AP in rabbits
in vivo. The fusion protein could be the prototype of a
well tolerated, long lasting protein drug that counters
thrombosis in patients
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